Xu‐Rong Jiang

1.4k total citations · 1 hit paper
17 papers, 1.1k citations indexed

About

Xu‐Rong Jiang is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Xu‐Rong Jiang has authored 17 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Immunology and 5 papers in Oncology. Recurrent topics in Xu‐Rong Jiang's work include Monoclonal and Polyclonal Antibodies Research (4 papers), Drug Transport and Resistance Mechanisms (3 papers) and Immune Response and Inflammation (3 papers). Xu‐Rong Jiang is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (4 papers), Drug Transport and Resistance Mechanisms (3 papers) and Immune Response and Inflammation (3 papers). Xu‐Rong Jiang collaborates with scholars based in United Kingdom, United States and China. Xu‐Rong Jiang's co-authors include Edwin Chang, Brenda Kusler, Gretchen S. Jimenez, Thea D. Tlsty, Geoffrey M. Wahl, Andrea Bodnár, Choy‐Pik Chiu, Marijke Sage, Adrian C. Newland and Shan Chung and has published in prestigious journals such as Nature Genetics, The Journal of Immunology and Nature Reviews Drug Discovery.

In The Last Decade

Xu‐Rong Jiang

17 papers receiving 1.1k citations

Hit Papers

Telomerase expression in ... 1999 2026 2008 2017 1999 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype
    1999 537 citations Xu‐Rong Jiang, Gretchen S. Jimenez et al. Nature Genetics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xu‐Rong Jiang United Kingdom 12 652 359 299 239 238 17 1.1k
Sandra Grau United Kingdom 8 702 1.1× 72 0.2× 520 1.7× 376 1.6× 136 0.6× 10 1.2k
Vanessa Ott United States 13 342 0.5× 360 1.0× 70 0.2× 498 2.1× 155 0.7× 17 1.1k
Jay S. Lillquist United States 15 499 0.8× 80 0.2× 106 0.4× 157 0.7× 160 0.7× 23 857
Karen Affleck United Kingdom 17 489 0.8× 141 0.4× 203 0.7× 113 0.5× 567 2.4× 24 1.2k
Kristie Clarkin United States 9 1.5k 2.2× 391 1.1× 105 0.4× 241 1.0× 1.1k 4.5× 12 2.1k
Susanne Meyer Germany 22 756 1.2× 83 0.2× 50 0.2× 162 0.7× 306 1.3× 46 1.3k
Joanne C. Pratt United States 21 999 1.5× 214 0.6× 197 0.7× 1.0k 4.2× 421 1.8× 28 1.9k
Margaret S. Dordal United States 10 432 0.7× 71 0.2× 92 0.3× 215 0.9× 129 0.5× 12 822
Shilpee Dutt India 21 902 1.4× 102 0.3× 55 0.2× 269 1.1× 295 1.2× 48 1.5k
Paul M. Grandgenett United States 21 594 0.9× 158 0.4× 58 0.2× 207 0.9× 341 1.4× 35 1.1k

Countries citing papers authored by Xu‐Rong Jiang

Since Specialization
Citations

This map shows the geographic impact of Xu‐Rong Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xu‐Rong Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xu‐Rong Jiang more than expected).

Fields of papers citing papers by Xu‐Rong Jiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xu‐Rong Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xu‐Rong Jiang. The network helps show where Xu‐Rong Jiang may publish in the future.

Co-authorship network of co-authors of Xu‐Rong Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Xu‐Rong Jiang. A scholar is included among the top collaborators of Xu‐Rong Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xu‐Rong Jiang. Xu‐Rong Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Wu, Bonnie, Shan Chung, Xu‐Rong Jiang, et al.. (2016). Strategies to Determine Assay Format for the Assessment of Neutralizing Antibody Responses to Biotherapeutics. The AAPS Journal. 18(6). 1335–1350. 42 indexed citations
3.
Wu, Yuling, Hyun‐Jun Kim, Xu Liu, et al.. (2015). A Neutralizing Antibody Assay Based on a Reporter of Antibody-Dependent Cell-Mediated Cytotoxicity. The AAPS Journal. 17(6). 1417–1426. 11 indexed citations
4.
Jiang, Xu‐Rong, An Song, Svetlana Bergelson, et al.. (2011). Advances in the assessment and control of the effector functions of therapeutic antibodies. Nature Reviews Drug Discovery. 10(2). 101–111. 241 indexed citations
5.
Banks, Douglas D., Himanshu S. Gadgil, Gary D. Pipes, et al.. (2007). Removal of Cysteinylation from an Unpaired Sulfhydryl in the Variable Region of a Recombinant Monoclonal IgG1 Antibody Improves Homogeneity, Stability, and Biological Activity. Journal of Pharmaceutical Sciences. 97(2). 775–790. 60 indexed citations
6.
Wu, Yu‐Ling, Xu‐Rong Jiang, Debra M. Lillington, Adrian C. Newland, & Stephen M. Kelsey. (2000). Upregulation of lipocortin 1 inhibits tumour necrosis factor-induced apoptosis in human leukaemic cells: a possible mechanism of resistance to immune surveillance. British Journal of Haematology. 111(3). 807–816. 12 indexed citations
7.
Wu, Yu‐Ling, Xu‐Rong Jiang, Debra M. Lillington, Adrian C. Newland, & Stephen M. Kelsey. (2000). Upregulation of lipocortin 1 inhibits tumour necrosis factor‐induced apoptosis in human leukaemic cells: a possible mechanism of resistance to immune surveillance. British Journal of Haematology. 111(3). 807–816. 28 indexed citations
8.
Jiang, Xu‐Rong, Gretchen S. Jimenez, Edwin Chang, et al.. (1999). Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nature Genetics. 21(1). 111–114. 537 indexed citations breakdown →
9.
Wu, Yu‐Ling, Xu‐Rong Jiang, Adrian C. Newland, & Stephen M. Kelsey. (1998). Failure to Activate Cytosolic Phospholipase A2 Causes TNF Resistance in Human Leukemic Cells. The Journal of Immunology. 160(12). 5929–5935. 39 indexed citations
10.
Jiang, Xu‐Rong, Stephen M. Kelsey, & Adrian C. Newland. (1997). Telomeres, Telomerase and Leukaemia. Hematology. 2(2). 101–111. 1 indexed citations
11.
Yang, Min, Najdat B. Nazhat, Xu‐Rong Jiang, et al.. (1996). Adriamycin stimulates proliferation of human lymphoblastic leukaemic cells via a mechanism of hydrogen peroxide (H2O2) production. British Journal of Haematology. 95(2). 339–344. 24 indexed citations
12.
Wu, Yu‐Ling, Xu‐Rong Jiang, Paul Allen, et al.. (1996). Modulation of surface TNF expression by human leukaemic cells alters their sensitivity to exogenous TNF. Leukemia Research. 20(1). 47–55. 13 indexed citations
13.
Jiang, Xu‐Rong, et al.. (1995). Circumvention of P‐glycoprotein‐mediated drug resistance in human leukaemic cells by non‐immunosuppressive cyclosporin D analogue, SDZ PSC 833. British Journal of Haematology. 90(2). 375–383. 42 indexed citations
14.
15.
Jiang, Xu‐Rong, Marion G. Macey, Peter W. Collins, & Adrian C. Newland. (1994). Characterization and modulation of drug transport kinetics in K562 cl.6 daunorubicin‐resistant cell line. British Journal of Haematology. 86(3). 547–554. 10 indexed citations
16.
Jiang, Xu‐Rong, et al.. (1992). The anti-leukaemic effects and the mechanism of sodium selenite. Leukemia Research. 16(4). 347–352. 23 indexed citations
17.
Jiang, Xu‐Rong, M. G. Macey, & Adrian C. Newland. (1991). Multidrug resistance in haematological malignancies.. PubMed. 48(4). 261–70. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sandra Grau Breakdown of academic impact, for papers by Vanessa Ott Breakdown of academic impact, for papers by Jay S. Lillquist Breakdown of academic impact, for papers by Karen Affleck Breakdown of academic impact, for papers by Kristie Clarkin Breakdown of academic impact, for papers by Susanne Meyer Breakdown of academic impact, for papers by Joanne C. Pratt Breakdown of academic impact, for papers by Margaret S. Dordal Breakdown of academic impact, for papers by Shilpee Dutt Breakdown of academic impact, for papers by Paul M. Grandgenett
Rankless by CCL
2026